Comparative Pharmacology
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 2 5 IN PLASTIC CONTAINER versus DIANEAL PD 2 W DEXTROSE 1 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 2 5 IN PLASTIC CONTAINER versus DIANEAL PD 2 W DEXTROSE 1 5 IN PLASTIC CONTAINER.
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER vs DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dialysis solution containing dextrose and electrolytes; dextrose provides osmotic gradient for ultrafiltration and caloric supplementation, while electrolytes maintain acid-base and electrolyte balance in peritoneal dialysis.
Dianeal PD-2 with Dextrose 1.5% is a peritoneal dialysis solution. Dextrose acts as an osmotic agent to create an osmotic gradient across the peritoneal membrane, facilitating the removal of waste products (urea, creatinine) and excess fluid from the blood into the peritoneal cavity, which is then drained out.
Intravenous infusion, 500-2000 mL per day as maintenance fluid; rate adjusted based on clinical status, typically 1-2 mL/kg/hour in adults.
Intraperitoneal: 2-2.5 L per exchange, 4 exchanges per day (continuous ambulatory peritoneal dialysis).
None Documented
None Documented
Terminal half-life: 2.5–3.5 hours. Clinically, this allows for rapid clearance; accumulation may occur in renal impairment.
Not applicable; dextrose utilization is capacity-limited with half-life of ~1.5 hours in normal circulation. In peritoneal dialysis, the osmotic effect declines over dwell time (2-4 hours) as dextrose is absorbed.
Renal: >95% as unchanged drug and metabolites. Biliary/fecal: <5%.
Dextrose is completely metabolized via glycolysis and the citric acid cycle to carbon dioxide and water; <1% excreted unchanged in urine. Osmotic agent effect terminated by peritoneal absorption and systemic metabolism.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution